Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CART22-65s Alone and With huCART19 in Relapsed/Refractory B-ALL
NCT03620058Phase 1Active, not recruiting
- Sponsor
- University of Pennsylvania
- Start
- Sep 2018
- Primary completion
- Jan 2036
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of CD22-CAR-T in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by University of Pennsylvania. Primary endpoints: Safety of CART22-65s at 15 months and Safety of combination CART22-65s and huCART19 at 15 months. Started Sep 2018; status: active, not recruiting.
02
Drugs
CD22-CAR-T
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT03620058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03620058.